Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study

Ricard Solà, Lluis Guirado, Joan Manuel Díaz, Carmen Facundo, Ignasi Gich, Esmirna Chuy, Antonio Cabezas

Research output: Contribution to journalArticleResearchpeer-review

4 Citations (Scopus)


At the moment, controversy has arisen about immunosuppression in aged kidney transplant recipients. We present our results on the efficacy and safety of induction treatment based on tacrolimus (FK506) and mycophenolate mofetil (MMF). We performed 72 transplants in patients of 60 years or older. Induction treatment consisted on (FK 506) 0.1 mg/kg/day and MMF 2 gr/day. Antilymphocyte serum was administered with delayed graft function. A total of 54 patients received kidneys from donors over 60 years old. Cold ischemia time was 16.4 h (S=5.7). Delayed graft function occurred in 35 patients (48.6%). Acute rejection was observed in nine patients (12.5%). Opportunistic infections were found in 19 patients (26.4%). Seven patients died due to sudden death (1), acute myocardial infarction (1), stroke (1), infection (3), and neoplasm (1). At 1, 2, and 3 years, serum creatinine was 145, 163, and 156 mmol/l; patient survival 93%, 90%, and 90%; graft survival 93%, 90%, and 87%; and death-censored graft survival 100%, 100%, and 97%, respectively. These immunosuppressive guidelines appear to be efficacious and safe in kidney transplant in elderly recipients. © 2004 Elsevier B.V. All rights reserved.
Original languageEnglish
Pages (from-to)129-131
JournalInternational Immunopharmacology
Publication statusPublished - 1 Jan 2005


  • Aged recipients
  • Kidney Transplant
  • Mycophenolate mofetil
  • Tacrolimus


Dive into the research topics of 'Tacrolimus/mycophenolate mofetil-based immunosuppression in aged kidney transplant. A prospective study'. Together they form a unique fingerprint.

Cite this